RLAY Dividend History & Analysis | N/A Yield
RLAY has a dividend yield of N/A and paid N/A per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| Symbol | Market Cap USD | Dividend Yield TTM | Yield on Cost 5y |
|---|---|---|---|
| BTX | 1,406 M | 13.4% | 7.37% |
| ABBV | 403,830 M | 3.77% | 9.44% |
| AMGN | 176,250 M | 3.75% | 6.02% |
| GILD | 150,882 M | 2.67% | 6.12% |
| HLN | 44,530 M | 1.74% | 2.46% |
| Symbol | Market Cap USD | Growth Rate (CAGR) | Payout Consistency |
|---|---|---|---|
| BTX | 1,406 M | 134% | 95.6% |
| HLN | 44,530 M | 30.1% | 100% |
| AMGN | 176,250 M | 7.84% | 100% |
| ABBV | 403,830 M | 5.98% | 100% |
| GILD | 150,882 M | 2.71% | 100% |
Similar Stocks with Attractive Dividends - Compare RLAY Dividends with its Peer-Group
3.75% Yield
3.77% Yield
2.67% Yield
1.74% Yield
RLAY Dividend History: as of January 2026
No dividends paid yet.RLAY Dividend FAQ
Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision-medicine firm that leverages computational protein-motion modeling to discover small-molecule therapeutics for oncology and genetic diseases. Its lead pipeline includes RLY-2608, a pan-mutant PI3Kα inhibitor being evaluated in breast cancer, solid tumors, and vascular malformations; aGal chaperone for Fabry disease; RLY-8161 targeting RAS-driven cancers; RLY-1013, an estrogen-receptor-alpha degrader; and lirafugratinib (RLY-4008), a receptor-tyrosine-kinase inhibitor. The company partners with D.E. Shaw Research for advanced modeling, Elevar Therapeutics for RLY-4008 commercialization, and Pfizer on a RLY-2608 + fulvestrant/atiraciclib combo.
What is the Dividend Yield of RLAY?
As of January 2026, RLAY`s dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 7.86.Does RLAY pay a dividend?
As of January 2026 RLAY does not pay a dividend.How often does RLAY pay dividends?
Over the last 12 months, RLAY has issued dividend payments.RLAY dividend forecast
Based on historical data, the forecasted dividends per share for RLAY for the next 4 payments are between 0 (+0.0%) and 0 (+0.0%).This suggests the dividend will remain relatively stable.
Will RLAY pay dividends in 2026?
The next Ex-Dividend date for Relay Therapeutics (RLAY) is currently unknown.What is the next Ex-Dividend Date for RLAY?
The next Ex-Dividend date for Relay Therapeutics (RLAY) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.What is the Dividend Growth of RLAY?
RLAY's average dividend growth rate over the past 5 years is -% per year.
What is the Yield on Cost of RLAY?
RLAY's 5-Year Yield on Cost is -%. If you bought RLAY's shares at 41.06 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.What is the Payout Consistency of RLAY?
RLAY Payout Consistency is 0.0%.
The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
Does RLAY have a good Dividend Yield?
RLAY`s % Dividend Yield is considered as unknown.What is the Dividend Payout Ratio of RLAY?
The Dividend Payout Ratio of RLAY is unknown.What is the Dividend Rating of RLAY?
RLAY`s Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.Key Metric Definitions
- Dividend Yield: Annual dividend per share divided by current share price.
- Dividend Growth Rate: Compound annual growth rate of annual dividend per share over the last 5 years.
- Payout Ratio: Percentage of earnings paid as dividends (TTM).
- Payout Consistency: % of eligible periods with uninterrupted or increased dividends, measured over the entire lifetime of the stock or fund.
- Payout Frequency: Number of dividends paid in the last 12m (TTM).
- Overall Dividend Rating: Proprietary composite score, quantified on a scale from 0 to +100. Ratings surpassing 70 are regarded as favorable, while those exceeding 85 are strong.
- Total Return: Price appreciation plus dividends over specified period.
- Market Cap: Figures are in millions of the corresponding currency.
Last update: 2026-01-06 02:38